
Cubs Win
6.3K posts

Cubs Win
@Cubswin2022
please don't take my stock market comments as investment advice my comments and opinions are my own and are not to be construed as Rec to buy or sell.











The $OTLK market is currently in a classic ‘wait-and-see’ phase. Until 29 July, the share price is likely to be driven primarily by speculation. Should the FDA approve LYTENAVA, this would mark a historic milestone for Outlook and signify its transition from a development-stage company to a commercial biotech firm.






I consider a $OTLK reverse split rather unlikely ahead of the FDA meeting, as Outlook has a strong binary catalyst ahead of it. Should LYTENAVA be approved, a reverse split is unlikely to be an issue. In the event of a negative FDA decision, however, it would be much more likely in order to secure the company’s listing on the Nasdaq.










